On March 16, the NYTimes ran two stories on Cerezyme, an expensive protein-based drug used to treat a rare genetic disorder, Gaucher’s disease. Both articles covered issues that might be emblematic of those that will be encountered when gene transfer applications are commercialized. One article described uncertainties clinicians face in establishing the appropriate dose for… Continue reading Cutting Recombinant Protein Pills?
Studies of Translation in Ethics and Medicine